| An evidence-based review of current anti-platelet options for STEMI patients. | |
| | |
MedLine Citation:
|
PMID: 22709725 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Drug-eluting stents are the default treatment for acute coronary syndromes, unless concerns or contraindications preclude dual antiplatelet therapy (DAPT). Platelet microemboli and mediators from activated platelets can undermine the restoration of perfusion. Therefore, ST-segment elevation MI (STEMI) patients should receive antiplatelet treatments regardless of reperfusion strategy. This review offers an evidence-based comparison of the P2Y(12) antagonists that have been evaluated in STEMI. While several studies support clopidogrel in STEMI, the benefits emerge several hours after administration and vary considerably reflecting genetic, cellular and clinical inter-individual differences. Although higher clopidogrel loading doses may improve outcomes, ticagrelor and prasugrel are more potent, produce less inter-individual variability, and show a faster onset of action. Ticagrelor and prasugrel improve outcomes compared to clopidogrel, with manageable bleeding risks, although further studies with a longer follow up are needed. Studies directly comparing ticagrelor and prasugrel are now needed. In the meantime, most current guidelines focus on clopidogrel and, therefore, need revision. While several polymorphisms influence platelet activity, CYP2C19 variants are the most consistently linked to clopidogrel responsiveness. Consensus groups should consider the studies needed to allow routine pharmacogenomic testing. The evidence-based use of P2Y(12) antagonists in DAPT should further reduce the morbidity and mortality associated with STEMI. |
| | |
Authors:
|
Guillaume Cayla; Johanne Silvain; Stephen A O'Connor; Jean-Philippe Collet; Gilles Montalescot |
Related Documents
:
|
2079095 - Animal model for chronic-abscess-forming peritonitis: histology and microbiology. 17888725 - Il-1beta secretion induced by aggregatibacter (actinobacillus) actinomycetemcomitans is... 1632835 - Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic aci... 2863285 - Identification of intracellular factor xiii in human monocytes and macrophages. 20797815 - The effect of shear stress on protein conformation: physical forces operating on bioche... 18023485 - A comparison of equine and bovine sera as sources of lipopolysaccharide-binding protein... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-6-16 |
Journal Detail:
|
Title: International journal of cardiology Volume: - ISSN: 1874-1754 ISO Abbreviation: - Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-6-19 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8200291 Medline TA: Int J Cardiol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved. |
Affiliation:
|
INSERM 937, Pitié-Salpêtrière University Hospital, Institut de cardiologie, Université Paris 6, France; Centre Hospitalo-Universitaire de Nîmes, service de cardiologie, Université Montpellier 1, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ion-sensing properties of 1D vanadium pentoxide nanostructures.
Next Document: Cardiac adipose tissue: A new frontier for cardiac regeneration?